Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methyl nalbuphine
- Development stage
- Unknown
- Lead developer
- Pluviaendo Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Subcutaneous
01
Overview
Methyl nalbuphine (also known as O-methylnalbuphine) is a semi-synthetic opioid compound and a derivative of nalbuphine. It acts as a mixed agonist-antagonist at opioid receptors, specifically functioning as an agonist at the kappa-opioid receptor (KOR) and an antagonist or partial agonist at the mu-opioid receptor (MOR). Developed and supplied as an active pharmaceutical ingredient (API) by Pluviaendo Pharmaceuticals, methyl nalbuphine is primarily utilized as a reference standard, a chemical intermediate in the synthesis of nalbuphine, or as a research tool in opioid receptor pharmacology.
- Other names
- N-cyclobutylmethyl-14-hydroxydihydronorcodeineN-cyclobutylmethyl14-hydroxydihydronorcodeineN-cyclobutylmethyl 14-hydroxydihydronorcodeineO-methyl nalbuphineO-methylnalbuphinemethylnalbuphine
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)σR (Sigma receptors)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on methyl nalbuphine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methyl nalbuphine.